Z

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357

Watchlist Manager
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Watchlist
Price: 21.31 CNY -0.93% Market Closed
Market Cap: 11.2B CNY
Have any thoughts about
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd?
Write Note

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Long-Term Debt
ÂĄ17.7m
CAGR 3-Years
116%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
ÂĄ104.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Debt
ÂĄ158.1m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
ÂĄ58.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
ÂĄ195.6m
CAGR 3-Years
43%
CAGR 5-Years
118%
CAGR 10-Years
42%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
ÂĄ192.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Glance View

Market Cap
11.2B CNY
Industry
Pharmaceuticals

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. emerged on the healthcare scene in China with an unwavering focus on improving allergy treatments. Founded in 1992, the company has carved a niche in the bio-pharmaceutical industry by specializing in the research, development, and manufacturing of allergen-specific immunotherapeutic products. At its heart, Wolwo operates with a clear mission: to diminish the burden of allergic diseases. The company leverages cutting-edge bio-pharmaceutical technologies to produce allergen detection and treatment products, thereby offering innovative solutions to millions affected by allergic conditions. As allergies become more prevalent worldwide, Wolwo's focus on this segment positions it as a critical player in the healthcare market. Wolwo’s business model revolves around the development and commercialization of standardized allergen products. It generates revenue primarily from the sale of its patented therapeutic solutions targeting common allergens such as pollen, dust mites, and pet dander. This involves a deep dive into biotechnology, where their R&D teams continuously innovate to refine product offerings. The company has earned regulatory approvals across various regions, which significantly bolsters its revenue stream and expands its market footprint. Beyond just product sales, Wolwo actively engages in educational programs aimed at raising awareness about allergies, thus creating a well-rounded approach not only in tackling allergic diseases but also in ensuring long-term consumer loyalty and brand trust in a rapidly evolving market.

Intrinsic Value
22.63 CNY
Undervaluation 6%
Intrinsic Value
Price
Z

See Also

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
17.7m CNY

Based on the financial report for Sep 30, 2024, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Long-Term Debt amounts to 17.7m CNY.

What is Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
116%

Over the last year, the Long-Term Debt growth was 19%. The average annual Long-Term Debt growth rates for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd have been 116% over the past three years .

Back to Top